IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion
study of IDP-023 administered as a single agent and in combination with or without
interleukin-2 (IL-2), and with or without daratumumab or rituximab to evaluate the safety,
tolerability and preliminary antitumor activity in patients with advanced hematologic
cancers.